๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Wuxi
Clinical trial register · China

Clinical Trials in Wuxi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Affiliated Hospital of Jiangnan University6 Changhai Hospital4 Novartis Pharmaceuticals3 Sanofi3 Wuxi People's Hospital3
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Wuxi

82 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
NCT07542379Prostate Cancer
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1
13
Wuxi
2026-08-31
Recruiting
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
NCT07649122Prostate Cancer
Norroy Bioscience Co., LTD
Phase 3
232
Nanjing, Wuxi
2026-08-31
Recruiting
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07779252Moderate to Severe Glabellar Lines
Ipsen
Phase 3
160
Guangzhou, Changsha, Nanjing, Wuxi, Jingโ€™an, Chengdu, Hangzhou, Beijing
2026-08-25
Not yet open
Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome
NCT07765914Nephrotic Syndrome
Children's Hospital of Fudan University
Phase 3
120
Shanghai, Changsha, Guiyang, Wuhan, Wuxi, Xiamen
2026-08-20
Recruiting
A Multicenter Prospective Observational Cohort Study for Digestive Tract Tumor Screening Using Multi-Target Blood and Fecal Biomarkers
NCT07769892Gastrointestinal Cancers
Xijing Hospital
Observational
5,000
Zhaoqing, Xi'an, Jinan, Mianyang, Wuwei, Wuxi
2026-08-10
Recruiting
Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
NCT07615101Prostate Cancer (Diagnosis)
Norroy Bioscience Co., LTD
Phase 3
365
Nanjing, Wuxi
2026-08-06
Not yet open
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
WEI XU
Not applicable
58
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
2026-08
Recruiting
Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
NCT07798778Metastatic Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University
Phase EARLY_PHASE1
18
Wuxi
2026-07-30
Recruiting
A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants
NCT07700953Healthy Participants
Abbisko Therapeutics Co, Ltd
Phase 1
30
Wuxi
2026-07-21
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
NCT07717905Chronic Spontaneous Urticaria
Bambusa Therapeutics
Phase 1/2
48
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jinzhou, Wuxi, Taiyuan, Xiโ€™an
2026-06-29
Recruiting
CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
NCT07615348Metastatic Clear Cell Renal Cell Carcinoma
Jinling Hospital, China
Phase 2
75
Nanjing, Wuxi
2026-06-16
Not yet open
A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance
NCT07622550Metastatic Colorectal Cancer (CRC)
Jiangsu Cancer Institute & Hospital
Phase 2
80
Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou
2026-06-15
Recruiting
A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model
NCT07712107Gastrointestinal Tumors
Xijing Hospital
Not applicable
10,000
Zhaoqing, Jinan, Mianyang, Wuwei, Wuxi
2026-06-15
Recruiting
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
NCT07604116Multiple System Atrophy (MSA), Parkinson's Disease (PD)
Synusight Biotech (Shanghai) Co., Ltd.
Phase 1
30
Wuxi, Shanghai
2026-06-15
Not yet open
Human Mass Balance Study of [ยนโดC]HRS-1893
NCT07656779Cardiomyopathies
Shandong Suncadia Medicine Co., Ltd.
Phase 1
6
Wuxi
2026-06
Recruiting
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
ADARx Pharmaceuticals, Inc.
Phase 2
30
Shenzhen, Guiyang, Zhengzhou, Baotou, Wuxi, Yantai, Beijing, Shandong
2026-05-21
Not yet open
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
NCT07516899Huntington Disease
Luye Pharma Group Ltd.
Phase 1
8
Wuxi
2026-04-30
Recruiting
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
NCT07459283Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1
10
Wuxi
2026-04-20
Active, closed
A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female Participants
NCT07537231Healthy Postmenopausal Women, Absorption, Metabolism, Excretion
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
6
Wuxi
2026-04-09
Not yet open
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
NCT07535762Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
Shanghai Jiao Tong University School of Medicine
Phase 2
36
Shanghai, Wuxi
2026-03-30
Not yet open
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
NCT07535710Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome, Cutaneous T Cell Lymphoma (CTCL)
Shanghai Jiao Tong University School of Medicine
Phase 1/2
37
Shanghai, Wuxi
2026-03-30
Not yet open
Safety and Efficacy Evaluation of an Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy (CMPA)
NCT07484035Cow's Milk Protein Allergy (CMPA)
Heilongjiang Feihe Dairy Co. Ltd.
Not applicable
124
Beijing, Foshan, Zhuhai, Xiangtan, Wuxi, Chengdu
2026-03-05
Not yet open
AI-Assisted Real-Time Endoscopic Characterization of Diminutive Colorectal Polyps in Non-Academic Hospitals
NCT07362524Colorectal Polyps
Shanghai Jiao Tong University School of Medicine
Not applicable
363
Nantong, Wuxi
2026-02-15
Not yet open
Portal Vein Thrombosis in Cirrhosis: Incidence, Outcomes and Anticoagulation
NCT07422701Portal Vein Thrombosis, Liver Cirrhosis
Peking University First Hospital
Observational
2,522
Beijing, Shenzhen, Hengshui, Qinhuangdao, Wuxi, Qingdao
2026-02-01
Recruiting
Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
NCT07505069Solid Tumors
Nanolattix Biotechnology Co., Ltd.
Phase EARLY_PHASE1
10
Wuxi
2026-01-29
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
Beijing, Changsha, Chengde, Chengdu, Guangzhou, Sanmenxia, Wuxi, Xi'an
2026-01-20
Not yet open
Multicenter Pediatric Low-Dose CT Protocol: Development and Clinical Verification
NCT07199101Radiation Dose Reduction
Beijing Children's Hospital
Not applicable
2,650
Beijing, Chongqing, Guangzhou, Baoding, Zhengzhou, Wuxi, Changchun, Xi'an
2026-01-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hangzhou, Jinan, Jingzhou
2025-10-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
3D1015 Injection for Patients With mCRPC
NCT07537010Metastatic Castration-resistant Prostate Cancer, mCRPC
Chunjing Yu
Phase 1
8
Wuxi
2025-08-27
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
Climb Bio, Inc.
Phase 2
45
Beijing, Shenzhen, Wuxi, Xi'an, Jinan, Yantai, Yibin
2025-08-25
Active, closed
Milk Free From A1-Type ฮฒ-Casein on Inflammation, Gastrointestinal Tolerance, and Pregnancy Outcomes
NCT06980376Healthy Pregnant Women
a2 Milk Company Ltd.
Not applicable
100
Foshan, Guangzhou, Wuxi, Xuzhou, Chengdu
2025-08-25
Recruiting
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT07239947Atopic Dermatitis
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Recruiting
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
Sanofi
Phase 2
99
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
By invitation
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
NCT07023848Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
Affiliated Hospital of Jiangnan University
Phase EARLY_PHASE1
10
Wuxi
2025-07-01
By invitation
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
NCT07023861Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
Affiliated Hospital of Jiangnan University
Phase EARLY_PHASE1
20
Wuxi
2025-07-01
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Active, closed
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
NCT07032597Mid Face Volume Deficit
AbbVie
Phase 3
252
Beijing, Wuhan, Nanjing, Wuxi, Shanghai, Hangzhou
2025-05-26
Not yet open
Evaluation of AI-Generated Clinical Advice by Physicians
NCT06980467Artificial Intelligence (AI)
Tsinghua University
Not applicable
8
Beijing, Wuxi
2025-05-15
Recruiting
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
NCT06970119Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 1/2
55
Wuxi, Tianjin
2025-05-14
Recruiting
Development and Validation of a Digital Twin-based Clinical Research System (X Town Stage I)
NCT06861283Chronic Disease
Shanghai 6th People's Hospital
Observational
1,500
Wuxi
2025-04-13
Recruiting
Clinical Intelligent Management System Pragmatic RCT
NCT06893068Primary Care Diseases
Tsinghua University
Not applicable
204
Wuxi
2025-04-13
Recruiting
Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants
NCT06912295Healthy Participants
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 1
76
Wuxi
2025-03-21
Recruiting
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
NCT06848400Gastric Lesion, Gastritis, Upper Gastrointestinal Bleeding (UGIB), Gastric Dysplasia
Nanfang Hospital, Southern Medical University
Not applicable
482
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Wuxi, Ganzhou, Mianyang
2025-03-03
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Recruiting
A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)
NCT05230914Stroke, Ischemic, Stroke, Acute
Xinqiao Hospital of Chongqing
Not applicable
1,846
Wuhu, Chongqing, Jiangmen, Haikou, Huai'an, Wuxi, Jingdezhen, Dalian
2024-12-12
Active, closed
Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
NCT06706310Chronic Hepatitis B
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
Pfizer
Phase 3
200
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
By invitation
Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients
NCT07162779PET CT
Affiliated Hospital of Jiangnan University
Not applicable
5
Wuxi
2024-10-29
Recruiting
A Phase 2 Study of HB0017 in Psoriasis Patients
NCT06592274Psoriasis (PsO)
Huabo Biopharm Co., Ltd.
Phase 2
200
Bengbu, Guangzhou, Changsha, Wuxi, Zhenjiang, Changchun, Jinan, Jining
2024-09-30
Recruiting
FeNO Detection in Asthma Diagnosis: A New Technology Approach
NCT06852911Bronchial Asthma, Airway Disease
Novlead Inc.
Not applicable
170
Shanghai, Wuxi
2024-09-12
Recruiting
Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours
NCT06430502Cancer, PD-L1 Gene Mutation
Wuxi People's Hospital
Not applicable
200
Wuxi
2024-05-07
Not yet open
Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
NCT05707468Oligometastatic Prostate Carcinoma
Changhai Hospital
Not applicable
200
Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai
2024-05-01
Active, closed
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
NCT06383052Metastatic Castration-resistant Prostate Cancer
Norroy Bioscience Co., LTD
Phase 1/2
30
Wuxi
2024-04-26
Recruiting
A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D
NCT06247046Irritable Bowel Syndrome With Diarrhea
Guangzhou Zhiyi Biotechnology Co., Ltd.
Phase 3
1,298
Wuxi, Binzhou
2024-03-16
By invitation
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
NCT06723665Prostate Cancer
Affiliated Hospital of Jiangnan University
Not applicable
50
Wuxi
2024-01-25
Recruiting
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
NCT06139575Prostate Cancer
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, รœrรผmqi
2023-12-07
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Recruiting
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
NCT06082037Lung Transplant Rejection
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours
NCT06404528Solid Tumors, Adult
Wuxi People's Hospital
Not applicable
300
Wuxi
2023-09-04
Recruiting
The Clinical Efficacy and Safety of Intratumoral Injection of Chemotherapy for Advanced Solid Tumors
NCT06430515Intratumoral Injection, Cancer
Wuxi People's Hospital
Not applicable
200
Wuxi
2023-09-01
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Recruiting
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
NCT06684028Cancer, Solid Malignancies
Affiliated Hospital of Jiangnan University
Not applicable
30
Wuxi
2023-07-12
Recruiting
Long-term Success Rate of Transvaginal Mesh for the Treatment of Pelvic Organ Prolapse: The Extended RCT Study
NCT05938881Pelvic Organ Prolapse
Peking Union Medical College Hospital
Observational
336
Foshan, Guangzhou, Changsha, Wuxi, Jinan, Xiโ€™an, Chengdu, รœrรผmqi
2023-06-29
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Recruiting
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
NCT05262010HPV InfectioN, HPV-Related Carcinoma
National Vaccine and Serum Institute, China
Phase 3
13,500
Hechi, Hezhou, Lianyuan, Wuxi, Yongji, Yuncheng, Mianyang, Neijiang
2022-06-04
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Beijing, Guangzhou, Changsha, Wuxi, Nanchang, Jinan, Chengdu, Yibin
2022-04-05
Active, closed
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
NCT04919226Neuroendocrine Tumors
ITM Solucin GmbH
Phase 3
259
Shanghai, Wuxi
2021-12-21
Active, closed
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925Primary Immune Thrombocytopenia
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Active, closed
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
NCT04684108Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
61
Bengbu, Beijing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Xiangyang, Wuxi
2021-11-04
Active, closed
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
NCT04922853Rectal Cancer, Neoadjuvant Chemotherapy
West China Hospital
Phase 3
554
Wuxi, Chengdu, Kunming
2021-08-26
Active, closed
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
Wenjun Cheng
Phase 2
56
Huai'an, Nanjing, Suzhou, Wuxi, Yancheng
2021-08-24
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
507
Fuzhou, Haikou, Zhengzhou, Changsha, Hengyang, Suzhou, Wuxi, Hangzhou
2018-11-28
Active, closed
Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients
NCT03777969Chronic Hepatitis b
Beijing Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Wuxi, Shanghai, Hangzhou
2018-06-29
Active, closed
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature
NCT03255694Dwarfism
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
360
Beijing, Wuhan, Changsha, Naning, Nanjing, Wuxi, Nanchang, Changchun
2017-05-12
Active, closed
Carotid Plaque Length to Predict Cardiovascular Events
NCT05409209Coronary Artery Disease
Changhai Hospital
Observational
3,000
Wuxi, Shanghai
2017-01-01
Active, closed
Association Between Carotid Plaque Length and Cardiovascular Outcomes
NCT05843487Coronary Artery Disease, Carotid Plaque
Changhai Hospital
Observational
3,000
Wuxi, Shanghai
2017-01-01
Active, closed
Association Between Carotid Plaque Length and Cardiovascular Events
NCT05159804Coronary Arteriosclerosis
Changhai Hospital
Observational
3,637
Wuxi, Shanghai
2017-01-01
Active, closed
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
NCT02375620Short Stature Children Born Small for Gestational Age (SGA)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
96
Beijing, Wuhan, Changsha, Wuxi, Nanchang, Changchun, Shanghai, Taiyuan
2015-04-23
Rows per page Showing 1–82 of 82
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/wuxi

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 82 of those studies with a site in Wuxi.

How many clinical trials are recruiting in Wuxi?

41 of the 82 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 13 have not yet opened recruitment, 23 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Wuxi), 82 studies
PhaseStudiesRecruitingShare
Phase 3211025.6%
Not applicable191023.2%
Phase 212514.6%
Phase 19511%
Observational839.8%
Phase 1/2647.3%
Phase EARLY_PHASE1647.3%
Phase 2/3101.2%

Most active sponsors

Lead sponsors with the most studies (Wuxi)
Lead sponsorStudiesRecruiting
Affiliated Hospital of Jiangnan University62
Changhai Hospital40
Changchun GeneScience Pharmaceutical Co., Ltd.30
Norroy Bioscience Co., LTD32
Novartis Pharmaceuticals31
Sanofi33
Shanghai Jiao Tong University School of Medicine30
Wuxi People's Hospital33
AbbVie20
Bambusa Therapeutics22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.